Should fluorescence cystoscopy be used for transurethral resection in patients with high-grade T1 bladder cancer?

Nature Clinical Practice Urology

Volumn 5, Issue 9, 2008, Pages 472-473

  Katz, Mark H ^a   Steinberg, Gary D ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID;

BLADDER CANCER; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CAUTERIZATION; COST BENEFIT ANALYSIS; CYSTECTOMY; CYSTOSCOPY; FALSE POSITIVE RESULT; FLUORESCENCE ANALYSIS; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; NOTE; PRIORITY JOURNAL; TRANSURETHRAL RESECTION;

EID: 51549110120     PISSN: 17434270     EISSN: 17434289     Source Type: Journal    
DOI: 10.1038/ncpuro1168     Document Type: Note

References (6)

1. Denzinger S et al. (2007) Does photodynamic transurethral resection of bladder tumor improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study. BJU Int 101: 566-569
2. Botteman MF et al. (2003) The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21: 1315-1330
3. Witjes JA and Douglass J (2007) The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer. Nat Clin Pract Urol 4: 542-549
4. Denzinger S et at. (2007) Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulink; acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology 69: 675-679
5. Stenzl A (2001) Fluorescence assisted transurethral resection of bladder tumors: Is it cost effective? Eur Urol 39: 31
6. Burger M (2007) Photodynamic diagnostics and non-invasive bladder cancer: Is it cost-effective in long-term application? Eur Urol 52: 142-147